



US 20090005663A1

(19) **United States**

(12) **Patent Application Publication**
Parker et al.

(10) **Pub. No.: US 2009/0005663 A1**

(43) **Pub. Date: Jan. 1, 2009**

(54) **NON-INVASIVE MEASUREMENT OF BLOOD ANALYTES**

(30) **Foreign Application Priority Data**

Jul. 4, 1998	(GB)	9814464.5
Nov. 13, 1998	(GB)	9824899.0
Nov. 19, 1998	(GB)	9825243.0

(75) Inventors: **Dawood Parker**, Whitland (GB);
David Keith Harrison, Durham (GB)

Publication Classification

(51) **Int. Cl.**
A61B 5/02 (2006.01)

(52) **U.S. Cl.** 600/326

(57) **ABSTRACT**

Correspondence Address:
EDWARDS LIFESCIENCES CORPORATION
LEGAL DEPARTMENT, ONE EDWARDS WAY
IRVINE, CA 92614 (US)

An apparatus for the measurement of at least one analyte in the blood of a patient, which includes a light source generating broadband light and a light-transmission arrangement having a plurality of transmitting fibers is positioned for simultaneously transmitting multiple wavelengths of the broadband light from the light source to the blood of the patient. The measurement apparatus further includes an optical fiber arrangement having a plurality of light detector fibers for leading multi-wavelength light, in spectrally unseparated form, transmitted through, or reflected from, the blood and a light detection arrangement for receiving the multi-wavelength light in its spectrally unseparated form from the optical fiber arrangement, for spectrally decomposing the received light, and for determining amplitudes of selected wavelengths of the decomposed light. The measurement apparatus utilizes a non-pulsatile element of the patient's blood for determining the measurement of at least one analyte in the blood as a function of the amplitudes of the selected wavelengths.


(73) Assignee: **Edwards Lifesciences Corporation**, Irvine, CA (US)

(21) Appl. No.: **12/206,662**

(22) Filed: **Sep. 8, 2008**

Related U.S. Application Data

(63) Continuation of application No. 11/049,035, filed on Jan. 25, 2005, now Pat. No. 7,424,317, which is a continuation of application No. 09/743,206, filed on Mar. 15, 2002, now Pat. No. 6,990,365, filed as application No. PCT/GB99/02127 on Jul. 2, 1999.







Fig. 1



An example of blood glucose levels during the day

Fig. 1a

NON-INVASIVE MEASUREMENT OF BLOOD ANALYTES

CROSS-REFERENCE TO RELATED APPLICATION(S)

[0001] This is a continuation of, and incorporates by reference, U.S. patent application Ser. No. 11/049,035, filed Jan. 25, 2005, now U.S. Pat. No. _____, which is a continuation of U.S. patent application Ser. No. 09/743,206, filed Mar. 15, 2002, now U.S. Pat. No. 6,990,365, which represents the U.S. National Phase, pursuant to 35 U.S.C. §371, of P.C.T. Application No. PCT/GB99/02127 filed Jul. 2, 1999, all of which are hereby incorporated by reference.

FIELD OF THE INVENTION

[0002] This invention relates to a novel monitor, particularly a monitor for the non-invasive measurement of glucose in eg diabetics and a method for determining glucose levels.

BACKGROUND OF THE INVENTION

[0003] Diabetes mellitus (abbreviated to diabetes) is the name for a group of chronic or lifelong diseases that affect the way the body uses food to make energy necessary for life. Primarily, diabetes is a disruption of carbohydrate (sugar and starch) metabolism and also affects fats and proteins. In people who have diabetes the glucose levels vary considerably being as high as 40 mmol/l and as low as 2 mmol/l. Blood glucose levels in people without diabetes vary very little, staying between 3 and 7 mmol/l. These levels follow the typical patterns shown in FIG. 1a.

[0004] Hyperglycaemia (High Blood Glucose)

[0005] Both insulin dependant diabetes (IDDM) and non-insulin dependant diabetes (NIDDM) are associated with serious tissue complications which characteristically develop after 10-20 years duration of diabetes. Diabetic eye disease, retinopathy, is the commonest cause of blindness in western countries in people under the age of 65 years. Diabetic renal disease, nephropathy, is an important cause of kidney failure in the community. Diabetic neuropathy affects the peripheral nerves causing impaired sensation and leg ulcers, and damage to the autonomic nervous system causes postural hypertension (low blood pressure on standing) and diarrhoea. Atherosclerosis is 24 times as high in diabetic as non-diabetic people and manifest as an increased frequency of myocardial infarction heart attacks), cerebrovascular disease (strokes) and the peripheral vascular disease (causing reduced circulation to the limbs and the risk of gangrene and amputation).

[0006] For many years it has been something of an article of faith in clinical diabetes that the cause of the complications is exposure of the tissues over many years to the higher than normal blood glucose levels which have been usual in most treated diabetic patients. Conclusive proof of this theory has only recently become available; the landmark Diabetes Control and Complications Trial (DCCT) in North America was announced in 1993 and showed that IDDM patients randomly assigned to an intensive and optimised insulin treatment programme designed to produce near-normal blood glucose levels had significantly less retinopathy, kidney disease and neuropathy over a 9-year period that patients assigned to ordinary treatment (ie poor control).

[0007] The DCCT has been a major stimulus to physicians around the world to renew efforts to improve control in dia-

betic patients, and to develop improved methods of obtaining good control and of monitoring these patients.

[0008] Hypoglycaemia (Low Blood Glucose)

[0009] An important additional finding in the DCCT was that the frequency of hypoglycaemia was three-fold higher in the well-controlled patients than those with ordinary control. This confirms the long-standing appreciation by physicians that hypoglycaemia is extremely frequent in IDDM, and especially so in those that are well controlled. There are many reasons for this including mistiming of insulin injections and food, erratic absorption of insulin, and impaired secretion in some diabetic patients of the so-called counter regulatory hormones such as adrenaline and glucagon that oppose the action of insulin.

[0010] About one third of IDDM patients have no warning symptoms of hypoglycaemia (eg sweating, nausea, blurred vision, palpitations) and they rely on intermittent self-monitoring of blood glucose to detect dangerously low glucose levels. The consequences of hypoglycaemia include impaired cognition and consciousness, and eventually coma.

[0011] Since the late 1970's, an increasing number of diabetic patients, mostly IDDM, have been measuring their own blood glucose concentrations using finger-prick capillary blood samples. Self blood glucose monitoring (SBGM) is used by diabetics in the home to detect hypoglycaemia or hyperglycaemia and take corrective action such as taking extra food to raise the blood glucose or extra insulin to lower the blood glucose. The measurements, which are made using a low-cost hand-held blood glucose monitor (BGM), also allow the physician to adjust the insulin dosage at appropriate times so as to maintain near normoglycaemia.

[0012] BGMs use either reflectance photometry or an electrochemical method to measure the glucose concentration. Reflectance photometry measures the amount of light reflected from the reagent-impregnated test strip that has reacted with a drop of blood. The operator pricks the finger of the patient or earlobe with a sterile lancet or uses anticoagulated whole blood collected in heparin and then places the blood on the test strip. The operator must place the blood onto the test strip at the time the monitor begins its timing sequence. This step is critical because under-timing (under-incubation) or over-timing (over-incubation) of the reaction may cause inaccurate measurements. At the audible signal, the operator wipes or blots the excess blood off the outside of the test strip. The operator then inserts the strip into the monitor for measurement.

[0013] In the electrochemical method a disposable single-use enzyme electrode test strip is used. When the test specimen is placed onto the test strip, an enzymatic reaction occurs that results in a current through the strip. The current is directly proportional to the concentration of glucose in the specimen.

[0014] The main disadvantages of SBGM systems are poor patient acceptance because the technique is painful, only intermittent assessment of diabetic control is possible and readings during the night or when the patient is otherwise occupied such as during driving are not possible. It is estimated that less than half of the IDDM patients in the US perform SBGM.

[0015] Further, glucose values obtained with BGMs may not agree with clinical laboratory results. Routine laboratory measurements of glucose are performed on either serum or plasma venous blood specimens that correspond with glucose concentrations measured on whole blood glucose analysers.

[0016] Whole blood glucose values are lower than those obtained from either serum or plasma. Although glucose is not a static component in human blood, changes in blood glucose concentration following food intake in normal and hyperglycaemic conditions are reasonably predictable. Similarly, the variation in glucose concentration as blood passes from arteries or capillaries to veins has also been documented. Therefore, over time, repeated measurement of blood glucose from the same patient may diverge widely. Also, blood obtained simultaneously by finger stick and venipuncture may not have the same glucose concentration. (Venous blood may contain 1 mmol/l less glucose than capillary blood if the same samples are obtained within 1-2 hours after carbohydrate intake).

[0017] Furthermore, the haematocrit of the patient (the volume of cells, mostly erythrocytes, expressed as a percentage of the volume of whole blood in a sample) influences glucose values, and whole blood glucose measurements must be corrected for this. Unfortunately, because BGMs cannot automatically correct for the haematocrit of the patient, an error of 5-15% may be introduced.

[0018] There is widespread agreement that for self-monitoring in the home the reluctant acceptance of the current finger-stick method is the main reason why the development of a non-invasive measurement technique has such high priority.

[0019] A non-invasive measurement device is known from U.S. Pat. No. 5,553,613. U.S. Pat. No. '613 describes a technique which uses the pulsatile component of the light intensity transmitted through the finger, from which to derive the glucose concentration noninvasively. It does this by using the wavelengths 805 nm, 925 nm, 970 nm and the range 1000-1100 nm. The measurements were made by transmission, ie light was passed through the finger. However, as mentioned above, U.S. Pat. No. '613 specifically relies upon the pulsatile component of the light transmitted through the patient. Such a pulsatile technique has clear disadvantages in that the pulsatile component of the light signal, whether transmitted or reflected, is less than 2% of the total signal. Thus, prior art devices which use only the pulsatile component are much less sensitive and much more vulnerable to patient movement which can cause interference which is in the order of a few hundred times the relevant signal.

[0020] Moreover, the pulsatile signal identifies arterial blood specifically. Whilst this is advantageous when considering the pulmonary circulation of a patient, it provides no information on the patient's systemic circulation which is important for glucose determination. Further, pulsatile techniques are limited to use on body extremities, eg finger, ear lobe or the ball of the foot in babies or neo-nates.

SUMMARY OF THE INVENTION

[0021] The present invention overcomes or mitigates the disadvantages of the prior art by using a plurality of closely associated transmitters and generators which allows an "average" evened out signal to be produced and is capable of utilising the non-pulsatile element of the patient's blood flow. In addition, a further advantage of the invention is that it allows the measurement of oxygen saturation (SO.sub.2). Furthermore, the invention permits the measurement of haemoglobin index (HbI) and/or temperature.

[0022] According to the invention we provide a device for the non-invasive measurement of one or more analytes in blood in a patient's body part which comprises a light trans-

mitter comprising a plurality of transmitting fibres positioned to transmit light to the body part and a light detector comprising a plurality of light detector fibres positioned to detect light transmitted through or reflected from the body part.

[0023] A preferred embodiment of the invention is one wherein the non-pulsatile element of the patient's blood is utilised. Thus, according to a further feature of the invention we provide a device for the non-invasive measurement of one or more analytes in blood in a patient's body part as herein before described which is adapted to measure the non-pulsatile element of a patient's blood. In a further preferred embodiment the device measures the pulsatile and non-pulsatile elements of a patient's blood. The device may be so adapted by being provided with a plurality of closely associated transmitters and generators which allows an "average" evened out signal to be produced.

[0024] Although various analytes may be measured, the detector of the invention is especially useful in measuring blood glucose level. We especially provide a device for the non-invasive measurement of one or more analytes in blood in a patient's body part as herein before described which is adapted to measure blood glucose levels.

[0025] The device may be capable of measuring other parameters either separately or in addition to blood glucose. An especially advantageous feature is the device may be adapted to measure blood oxygen saturation (SO.sub.2).

[0026] As a further preferred embodiment we provide a device which is adapted to measure the haemoglobin index (HbI) and/or temperature of a patient's blood.

[0027] The device may be adapted for use, with any body part although it is preferable that it can be a finger or thumb.

[0028] The number of transmitter fibres may vary although we have found that 18 transmitter fibres works well. The number of detector fibres may be the same or different to the number of transmitter fibres, but may vary and we have found that 12 detector fibres works well. The diameter of the detector and the transmitter fibres may be the same or different and may vary, a diameter of 250 .mu.m is preferred.

[0029] The detector fibres are preferably positioned to detect reflected light rather than transmitted light.

[0030] The wavelength used in the transmitter fibres will generally be from 500 to 1100 nm. However, it is a further feature of the invention to provide a detector as hereinbefore described which also measures haemoglobin index (HbI) and/or oxygen saturation (SO.sub.2) of blood. For such measurement, specific wavelengths are used, namely 500.9 nm, 528.1 nm, 549.5 nm, 561.1 nm, 572.7 nm and 586.3 nm. The preferred wavelengths for measuring blood glucose are from 800 nm to 1100 nm.

[0031] According to a further feature of the invention we provide a method of measuring blood glucose levels which comprises placing a non-invasive measuring device as hereinbefore described against a body part of a patient and using the detector to measure the light transmitted through or reflected from the body part.

[0032] In a yet further feature of the invention we provide a device according to as herein before described programmed so as to calculate one or more of the haemoglobin index, the oxygen index and the blood oxygen saturation. Clearly, since blood oxygen saturation is dependent upon both the haemoglobin index and the oxygen index, the computer is programmed so as to calculate these equations first if blood oxygen saturation is to be calculated.

[0033] We also provide a computer programme product comprising a computer readable medium having thereon computer programme code means, when said programme is loaded, to make the computer execute a procedure to calculate one or more of the haemoglobin index, the oxygen index and the "whole blood" oxygen saturation as herein before described.

BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The invention will now be illustrated but in no way limited by reference to the following example and drawings in which;

[0035] FIG. 1 is a plot of the predicted glucose values against the measured glucose values; and

[0036] FIG. 1a is a graph comparing normal blood glucose levels with those of a diabetic.

DETAILED DESCRIPTION

EXAMPLE 1

[0037] Glucose Measurement

[0038] In vivo measurements using the MCPD spectrophotometer were carried out at 10 min intervals on the fingertips of 8 volunteers during the course of glucose tolerance tests and the results compared with those measured using a conventional blood glucose monitor. In addition, parallel measurements of local blood flow (laser Doppler flux) and temperature were made.

[0039] The analysis which is presented here uses the same wavelength range used in the previous glucose studies carried out namely: 805 nm, 925 nm, 970 nm and the broadband average 1000-1100 nm, but additionally wavelengths sampled at regular intervals in the entire range 800 nm to 1100 nm. Intervals of 1.96 nm worked well.

[0040] Earlier work demonstrated that the glucose-dependent signal emanates from haemoglobin. Furthermore, although the 805 nm wavelength could be used to compensate for small changes in haemoglobin concentration large changes continued to interfere with the sensitivity for glucose. It was furthermore recognised that changes in haemoglobin oxygenation would cause absorption changes from 800 nm to 1100 nm. As in all physiological measurements carried out in the peripheral circulation, temperature is also likely to be a controlling parameter. In the novel analysis carried out on the intensity spectra in the experiments carried out here, the three parameters haemoglobin concentration, oxygen saturation and temperature were introduced into the multiple linear regression analysis along with the near infrared parameters previously used.

[0041] Experimental

[0042] 13 glucose tolerance tests (GTTs) were carried out on 8 different volunteers. In one case, 200 ml water was given instead of the solution of 75 g glucose in 200 ml water; a real GTT was subsequently carried out on the same volunteer. In one volunteer five GTTs were carried out on separate occasions. One volunteer had diabetes.

[0043] All measurements were carried out with an Otsuka Optonics Photal MCPD-1000 photodiode array lightguide spectrophotometer. The 0.2 mm slit was used for the diffraction grating giving a full width at half maximum transmission of 7.2 nm, comparable with the glucose monitor. Using the supplied software, the instrument allows access to data points at 1.94 nm intervals within the wavelength range 300-100 nm. The range displayed during the glucose experiments was

500-1100 nm. In order to mimic the broad bandwidth characteristics of the previous glucose monitor above 100 nm, all measurements were averaged over the range 1000-1100 nm. Quartz lightguides were used in conjunction with a 400 W quartz-halogen light source.

[0044] A lightguide bundle, which consisted of 18 transmitting and 12 receiving fibres each of 250 .mu.m diameter, was attached to the fingertip of the subject by means of a laser Doppler probe holder. Recordings of spectra were made at 10 min intervals throughout the test using the MCPD spectrophotometer described above. These recordings were accompanied by parallel measurements of glucose concentrations in blood, obtained by pinprick of a contralateral finger with the aid of a Softelix pro lancet system, using a Boehringer Mannheim Advantage® glucose monitor. The lightguide was removed from the finger after each measurement and new dark and reference spectra recorded before each new measurement. A total of 13 measurements were carried out over a 2 hour period.

[0045] Careful selection of integrating time and the intensity of the reference spectrum enabled the simultaneous record of spectra that covered not only the range 800-1100 nm, but also the visible range from 500-600 nm. This enabled the evaluation of skin haemoglobin saturation (SO.sub.2) and haemoglobin concentration (HbI) (Harrison D K et al, (1993) Phys Meas 14: 241-52) from the same spectra as those being analysed for glucose (see below).

[0046] A Moor Instruments DRT4 laser Doppler perfusion monitor was used to measure blood flow changes in the adjacent finger. The probe incorporated a thermal sensor, which was used to measure skin temperature (note: also on the adjacent finger) throughout the experiment.

[0047] Derivation of HbI and SO.sub.2

[0048] HbI and SO.sub.2 were derived from the absorption spectra measured from 500.8 to 586.3 nm using a computer program VOXYG written for the purpose. The program carried out the following calculations.

[0049] Haemoglobin Index

$$\text{HbI} = \frac{(b-a)/27.1 + (c-b)/21.4 + (c-e)/23.3 + (c-f)/13.6}{*100}$$

[0050] Oxygenation Index

$$\text{OXI} = \frac{(e-d)/11.7 - (d-c)/11.6}{*100/\text{HbI}}$$

[0051] Oxygen Saturation

$$\text{SO.sub.2} = 100 * (\text{OXI} + 0.43) / 1.5$$

[0052] where a=absorption value at 500.9 nm

[0053] b=absorption value at 528.1 nm

[0054] c=absorption value at 549.5 nm

[0055] d=absorption value at 561.1 nm

[0056] e=absorption value at 572.7 nm

[0057] f=absorption value at 586.3 nm

[0058] Multiple Linear Regression Analysis

[0059] A data file A was created containing the full absorption spectral data (800-1100 nm in 1.96 nm steps) from all 12 GTTs in the series. The absorption values in the file are defined in "absorption units" referred to here as ABUs. The other data contained in the file were time, experiment identification, glucose concentration (invasive), HbI, SO.sub.2, temperature, and laser Doppler flux.

[0060] A number of secondary files were created whereby a sequence of "normalisations" of the data were performed:

[0061] B—ABU data of A was normalised by subtraction of the absorption of the values at 802 nm (ie ABU.sub.A-ABU.sub.802). This is similar to the way in which previous data was treated.

[0062] C—ABU data of B was further normalised by division by the HbI value (ie ABU.sub.B/HbI). This was designed to take into account of the results of the in vitro experiments which showed that normalisation at, then, 805 nm did not fully compensate for changes in haemoglobin concentration.

[0063] D—ABU data of C was further normalised by division by the SO.sub.2 value (ie

[0064] ABU.sub.C/SO.sub.2) to take into account the influence of changes in the relative concentrations of oxygenated haemoglobin (HbO.sub.2) and deoxygenated haemoglobin (Hb) on the infrared spectrum.

[0065] E—SBU data of D was yet further normalised by subtraction of the value at the assumed water peak (ie ABU.sub.D-ABU.sub.949) in an attempt to take into account changes in water content.

[0066] The types and orders of normalisations may vary, and the above are examples.

[0067] The above files were then subjected to multiple linear regression, analysis using SPSS for Windows 6.1.2. All of the wavelengths available in the above data files, ie 800 nm to 1100 nm in 1.96 nm steps were entered as independent variables. The results of the multiple wavelength regressions are given below. The regressions include only the spectral data and not HbI, SO.sub.2 or temperature as further independent variables at this stage.

[0068] Standard Error (SE) No of Wavelengths r (mM)
Included A 0.48 2.81 4 B 0.89 1.69 37 C 0.80 2.05 21 D 0.89 1.61 31 E 0.93 1.40 48

[0069] The predicted values from the last correlation using data file E are plotted against the measured glucose values in FIG. 1. The predicted values are given as standardised to the mean and number of standard deviations on the left hand side of the y-axis and as mM on the right hand side.

[0070] The results obtained using the multi-wavelength analysis are significant improvements to those using the original parameters applied to the collective results. FIG. 1 could indicate that the method may eventually allow a universal calibration, or at least one based on a particular individual, particularly if the ways in which the spectra are normalised are varied.

[0071] Above multiple regression analyses result in regression equations whose coefficients can be incorporated into an

equation to produce a new parameter “calculated Glucose”. This, together with the parameters HbI, SO.sub.2 and temperature can then be incorporated into a further regression equation for each individual GTT.

[0072] Least squares fitting of mean “calibration spectra” recorded from the GTT series could be used for a universal or individual calibration.

What is claimed is:

1. A method for measuring blood oxygen saturation in blood of a patient, comprising:

placing against a body part of the patient an apparatus for non-invasive measurement of at least one analyte in the blood in the body part of the patient;

transmitting light via a plurality of transmitting fibers to the body part of the patient;

detecting light transmitted from, or reflected through, the body part of the patient via a plurality of light detector fibers;

determining a measurement of at least one analyte in the blood utilizing a non-pulsatile element of the blood; and measuring blood oxygen saturation (SO₂) using the equation:

$$SO_2=100*(OXI+0.43)/1.5,$$

wherein, OXI is the oxygenation index of the blood and is defined by the equation:

$$OXI=[(e-d)/11.7-(d-c)/11.6]*100/HbI,$$

wherein, HbI is the hemoglobin index of the blood and is defined by the equation:

$$HbI=[(b-a)/27.1+(c-b)/21.4+(c-e)/23.3+(c-f)/13.6]*100,$$

and wherein:

a=absorption value at 500.9 nm wavelength of light;

b=absorption value at 528.1 nm wavelength of light;

c=absorption value at 549.5 nm wavelength of light;

d=absorption value at 561.1 nm wavelength of light;

e=absorption value at 572.7 nm wavelength of light; and

f=absorption value at 586.3 nm wavelength of light.

* * * * *

专利名称(译)	血液分析物的无创测量		
公开(公告)号	US20090005663A1	公开(公告)日	2009-01-01
申请号	US12/206662	申请日	2008-09-08
[标]申请(专利权)人(译)	爱德华兹生命科学公司		
申请(专利权)人(译)	爱德华生命科学公司		
当前申请(专利权)人(译)	怀特兰研究有限公司		
[标]发明人	PARKER DAWOOD HARRISON DAVID KEITH		
发明人	PARKER, DAWOOD HARRISON, DAVID KEITH		
IPC分类号	A61B5/02 A61B5/00 B65H23/18		
CPC分类号	A61B5/14532 B65H23/18 A61B5/14551 A61B5/1455		
优先权	1998024899 1998-11-13 GB 1998025243 1998-11-19 GB 1998014464 1998-07-04 GB PCT/GB1999/002127 1999-07-02 WO		
其他公开文献	US7774037		
外部链接	Espacenet USPTO		

摘要(译)

用于测量患者血液中的至少一种分析物的装置，其包括产生宽带光的光源和具有多个传输光纤的光传输装置，用于同时传输来自所述宽带光的多个波长的宽带光。光源到患者的血液。该测量装置还包括光纤装置，该光纤装置具有多个光检测器光纤，用于以光谱未分离的形式引导多波长光，透射通过血液或从血液反射，以及用于接收多波长光的光检测装置。它与光纤布置的光谱未分离的形式，用于光谱分解所接收的光，并用于确定分解的光的所选波长的幅度。测量装置利用患者血液的非脉动元件来确定血液中至少一种分析物的测量值，作为所选波长的幅度的函数。

